CICC Research Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price

Eli Lilly and Company (NYSE:LLY) had its price target increased by CICC Research from $1,060.00 to $1,107.00 in a research note released on Wednesday,MarketScreener reports. They currently have a neutral rating on the stock.

A number of other brokerages have also weighed in on LLY. Morgan Stanley raised their target price on Eli Lilly and Company from $1,290.00 to $1,313.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Scotiabank reissued an “outperform” rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Berenberg Bank raised their target price on Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a report on Tuesday, December 2nd. Rothschild & Co Redburn boosted their price target on shares of Eli Lilly and Company from $775.00 to $830.00 and gave the company a “neutral” rating in a research report on Monday, January 26th. Finally, Daiwa Securities Group set a $1,230.00 price target on shares of Eli Lilly and Company and gave the company a “buy” rating in a report on Tuesday, December 16th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,218.88.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded up $20.13 on Wednesday, reaching $1,058.40. The stock had a trading volume of 374,117 shares, compared to its average volume of 3,343,962. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The stock has a market cap of $1.00 trillion, a P/E ratio of 46.12, a price-to-earnings-growth ratio of 1.18 and a beta of 0.39. The company has a 50 day simple moving average of $1,051.78 and a 200 day simple moving average of $904.70.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating the consensus estimate of $7.48 by $0.06. The business had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 112.50%. The company’s revenue for the quarter was up 42.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is currently 26.14%.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of LLY. Lazard Freres Gestion S.A.S. increased its holdings in shares of Eli Lilly and Company by 114.3% in the second quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock valued at $60,253,000 after buying an additional 41,222 shares in the last quarter. Exencial Wealth Advisors LLC increased its position in Eli Lilly and Company by 189.6% during the third quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock worth $13,283,000 after acquiring an additional 11,396 shares during the period. Rede Wealth LLC acquired a new position in shares of Eli Lilly and Company in the third quarter valued at $487,000. Central Pacific Bank Trust Division boosted its stake in shares of Eli Lilly and Company by 25.8% in the 3rd quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock valued at $6,859,000 after purchasing an additional 1,843 shares in the last quarter. Finally, Oak Family Advisors LLC bought a new position in shares of Eli Lilly and Company in the third quarter valued at about $1,979,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly agreed to acquire Orna Therapeutics for up to $2.4B — expands Lilly’s RNA platform and pipeline diversification, supporting long?term growth expectations. Eli Lilly to Acquire Orna Therapeutics
• Positive Sentiment: Strong Q4 results and a bold FY2026 EPS outlook reinforce revenue momentum (GLP?1/obesity franchise) and justify premium valuation — a primary driver behind recent analyst bullishness. How to Play Eli Lilly Stock Following a Robust Q4
• Positive Sentiment: Analyst upgrades and new buy ratings have followed the earnings print, which can support further upside as fund managers adjust allocations. LLY Gets New ‘Buy Rating’ After Strong Earnings
• Positive Sentiment: Local governments approved large manufacturing investments (Huntsville ~$6B, Katwijk ~$3B) — expands capacity for commercial supply and insulates operations, supporting long?term revenue growth and supply chain resilience. Huntsville City Council approves Eli Lilly agreement
• Neutral Sentiment: Regulatory filing shows Lilly built about $1.5B of pre?launch inventory for its experimental oral weight?loss pill (orforglipron) ahead of an April FDA decision — signals management expects approval but creates execution/working?capital exposure if outcomes differ. Lilly builds $1.5B stockpile ahead of FDA decision
• Neutral Sentiment: Industry partnership activity (Lilly + Innovent) and deals signal strategic expansion in China and beyond, but commercial impact will play out over multiple years. Lilly, Innovent go ‘beyond traditional licensing’
• Negative Sentiment: Broader sector themes — pricing pressure, patent cliffs and a pharma “reset” — remain headwinds that could compress future margins or slow growth if pricing/payer dynamics shift. These macro factors add risk to valuation despite strong near?term results. Prices, pipelines and patent cliffs: Inside pharma’s big reset

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.